Co-Authors
This is a "connection" page, showing publications co-authored by Olga Korolkova and Amos Sakwe.
Connection Strength
2.816
-
Korolkova OY, Widatalla SE, Williams SD, Whalen DS, Beasley HK, Ochieng J, Grewal T, Sakwe AM. Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies. Cells. 2020 08 07; 9(8).
Score: 0.667
-
Korolkova OY, Widatalla SE, Whalen DS, Nangami GN, Abimbola A, Williams SD, Beasley HK, Reisenbichler E, Washington MK, Ochieng J, Mayer IA, Lehmann BD, Sakwe AM. Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. PLoS One. 2020; 15(4):e0231711.
Score: 0.653
-
Black PJ, Ball DD, Edwards AD, Macintosh AR, Sakwe NI, Vuong NB, Korolkova OY, Sharma V, Misra S, Sakwe AM. Sequential Invasion Assays Identify Carbonic Anhydrase IX as a Driver of Invasiveness in Epithelial Triple-Negative Breast Cancer cells. Am J Physiol Cell Physiol. 2026 Apr 21.
Score: 0.248
-
Vuong NB, Korolkova OY, Izban MG, Sakwe NI, McIntosh AR, Ball DD, Black PJ, Edwards AD, Ballard BR, Adunyah SE, Sakwe AM. Contribution of Mesenchymal-like and Epithelial Cellular Subsets to Chemotherapy Resistance in Triple-Negative Breast Cancer. Int J Mol Sci. 2026 Mar 31; 27(7).
Score: 0.247
-
Vuong NB, Korolkova OY, Izban M, Sakwe NI, McIntosh AR, Ball D, Black P, Edwards A, Ballrad BR, Adunyah SE, Sakwe AM. Contribution of Mesenchymal-like and Epithelial Cellular Subsets to Chemotherapy Resistance in Triple-Negative Breast Cancer. bioRxiv. 2025 Nov 03.
Score: 0.240
-
Beasley HK, Widatalla SE, Whalen DS, Williams SD, Korolkova OY, Namba C, Pratap S, Ochieng J, Sakwe AM. Identification of MAGEC2/CT10 as a High Calcium-Inducible Gene in Triple-Negative Breast Cancer. Front Endocrinol (Lausanne). 2022; 13:816598.
Score: 0.186
-
Widatalla SE, Korolkova OY, Whalen DS, Goodwin JS, Williams KP, Ochieng J, Sakwe AM. Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors. Carcinogenesis. 2019 08 22; 40(8):998-1009.
Score: 0.156
-
Whalen DS, Widatalla SE, Korolkova OY, Nangami GS, Beasley HK, Williams SD, Virgous C, Lehmann BD, Ochieng J, Sakwe AM. Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility. Oncotarget. 2019 Jan 04; 10(2):133-151.
Score: 0.149
-
Kenchappa DB, Korolkova O, Sakwe N, Odiase P, Izban MG, Sakwe A, Ochieng J. Fetuin-A Modulates Tumor Growth and Invasion in a Basal-like Triple Negative Breast Cancer Cell line, MDA-MB-468. J Pharm Pharmacol Res. 2025; 9(1):1-9.
Score: 0.057
-
Rana T, Korolkova OY, Rachakonda G, Williams AD, Hawkins AT, James SD, Sakwe AM, Nian H, Wang L, Yu C, Goodwin JS, Izban MG, Offodile RS, Washington MK, Ballard BR, Smoot DT, Shi XZ, Forbes DS, Shanker A, M'Koma AE. Correction: Linking bacterial enterotoxins and alpha defensin 5 expansion in the Crohn's colitis: A new insight into the etiopathogenetic and differentiation triggers driving colonic inflammatory bowel disease. PLoS One. 2024; 19(5):e0304732.
Score: 0.054
-
Ochieng J, Korolkova OY, Li G, Jin R, Chen Z, Matusik RJ, Adunyah S, Sakwe AM, Ogunkua O. Fetuin-A Promotes 3-Dimensional Growth in LNCaP Prostate Cancer Cells by Sequestering Extracellular Vesicles to Their Surfaces to Act as Signaling Platforms. Int J Mol Sci. 2022 Apr 05; 23(7).
Score: 0.047
-
Rana T, Korolkova OY, Rachakonda G, Williams AD, Hawkins AT, James SD, Sakwe AM, Hui N, Wang L, Yu C, Goodwin JS, Izban MG, Offodile RS, Washington MK, Ballard BR, Smoot DT, Shi XZ, Forbes DS, Shanker A, M'Koma AE. Linking bacterial enterotoxins and alpha defensin 5 expansion in the Crohn's colitis: A new insight into the etiopathogenetic and differentiation triggers driving colonic inflammatory bowel disease. PLoS One. 2021; 16(3):e0246393.
Score: 0.043
-
Williams AD, Korolkova OY, Sakwe AM, Geiger TM, James SD, Muldoon RL, Herline AJ, Goodwin JS, Izban MG, Washington MK, Smoot DT, Ballard BR, Gazouli M, M'Koma AE. Correction: Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease. PLoS One. 2017; 12(12):e0189551.
Score: 0.035
-
Williams AD, Korolkova OY, Sakwe AM, Geiger TM, James SD, Muldoon RL, Herline AJ, Goodwin JS, Izban MG, Washington MK, Smoot DT, Ballard BR, Gazouli M, M'Koma AE. Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease. PLoS One. 2017; 12(8):e0179710.
Score: 0.034